FTC proposes framework for the transfer of patent rights in the pharmaceutical industry

by Saul Ewing Arnstein & Lehr LLP
Contact

Summary
The FTC has proposed amendments to the premerger notification Rules to codify prior FTC guidance concerning when a transaction involving the transfer of rights to a patent in the pharmaceutical and medicine manufacturing industry is reportable under the Hart-Scott-Rodino Act.

The Federal Trade Commission (FTC) recently proposed amendments to the premerger notification rules (Rules) to codify prior FTC guidance concerning when a transaction involving the transfer of rights to a patent in the pharmaceutical and medicine manufacturing industry is reportable under the Hart-Scott-Rodino Act (HSR). Specifically, the FTC proposes to amend §801.1 and §801.2 of the Rules to "reflect the longstanding [FTC Premerger Notification Office (PNO)] staff position that a transaction involving the transfer of exclusive rights to a patent in the pharmaceutical industry, which typically takes the form of an exclusive license, is reportable under the Act." The proposed Rules also define and apply the concepts of "all commercially significant rights," "limited manufacturing rights," and "co-rights" to determine whether the transferred rights constitute a reportable asset acquisition.

Although the FTC is limiting the proposed Rules to the pharmaceutical industry, the transfer of exclusive rights to a patent in other industries remains a potentially reportable event under the Act, and thus, parties in other industries should consult PNO staff in such circumstances. Comments to the proposed Rules must be received on or before October 25, 2012.

Background

Currently, acquisition of a patent is an asset acquisition under HSR and is therefore a reportable transaction if the reporting thresholds are met – and this will not change under the proposed Rules. In the case of a transfer of rights to "use a patent to exclusively manufacture a product, develop the product for all potential uses, and sell that product without restriction," however, the analysis is "more challenging." Generally, "[i]f the licensor retains the right to manufacture, the deal is, in most instances, non-reportable." Under the current PNO approach, such agreements are considered distribution agreements rather than asset acquisitions. PNO staff found that the focus of its analysis in such cases was on what rights the licensor granted and those it retained, which rights are typically classified as "co-rights" and "manufacturing rights."

All Commercially Significant Rights

As defined in the proposed Rules, "all commercially significant rights" flow from the exclusive rights to a patent. "As a result of these exclusive rights, only the recipient has the right to use the patent in a particular therapeutic area, or specific indications within that therapeutic area, to generate eventual profits (some of which will be shared with the licensor through royalties or other revenue sharing agreements). The recipient alone gains all commercially significant rights to the patent through the transfer of the exclusive rights to it."

Because PNO's analysis focuses on the substance and not the form of the transfer, any transfer of exclusive rights to a patent in the pharmaceutical industry is a potentially reportable event, even if the transfer is characterized as an exclusive license. The proposed Rules focus on the transfer of exclusive rights to a pharmaceutical patent in a particular "therapeutic area." A "therapeutic area" covers the intended use for the patent, such as neurological, and includes all "indications." An "indication" encompasses a narrower segment of a "therapeutic area," such as Parkinson's disease within the neurological "therapeutic area."

Retention of Co-Rights

Under current policy, retention of co-rights does not render a license non-exclusive. Under the proposed Rules, this approach will not change because under the proposed "all commercially significant rights" concept the profits result from a potentially reportable transfer to the licensee of the exclusive right to use the patent. By way of example, a licensor may grant a licensee the exclusive right to make, use and sell a product, but retain rights to assist in maximizing sales of the licensed product. In the view of PNO staff, the licensor does not retain the right to use the patent in the same therapeutic area. Consequently, "the all commercially significant rights test reflects the PNO staff's existing position on the reportability of exclusive licenses in which the patent holder retains co-rights."

Retention of Manufacturing Rights

Under the proposed Rules, retention by the licensor of the right to manufacture "exclusively for the licensee" is a potentially reportable asset acquisition because "all commercially significant rights" have passed to the licensee. This contrasts with PNO staff's prior view that retention of the right to manufacture was a non-reportable event because the license appeared to be a distribution agreement. Under the proposed Rules, "when the licensor retains the right to manufacture exclusively for the licensee, it will retain ‘limited manufacturing rights.'" In the view of PNO staff, "the licensor is still transferring all commercially significant rights to the licensee and a potentially reportable asset acquisition is taking place."

Conclusion

In summary, the proposed Rules appear to broaden the types of transactions subject to reporting, although the FTC estimates the increase at less than 2 percent. Notwithstanding, the proposed Rules are meant to clarify the analysis of the reportability of transfers of pharmaceutical rights and to clarify that the retention of "limited manufacturing rights" and "co-rights" does not affect whether the transfer of "all commercially reasonable rights" has occurred. We continue to monitor the rulemaking progress and will report on any amendments and adopted final Rules. The complete text of the proposed Rules can be accessed here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Saul Ewing Arnstein & Lehr LLP | Attorney Advertising

Written by:

Saul Ewing Arnstein & Lehr LLP
Contact
more
less

Saul Ewing Arnstein & Lehr LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.